A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults with Severe Eosinophilic Asthma treated with Benralizumab.

Trial Identifier: D3250R00102
Sponsor: AstraZeneca
NCTID:: NCT05440656
Start Date: June 2022
Primary Completion Date: June 2025
Study Completion Date: June 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Greece Alexandroupolis, Greece, 68100
Greece Athens, Greece, 17562
Greece Athens, Greece, 11525
Greece Athens, Greece, 11521
Greece Athens, Greece, 10676
Greece Athens, Greece, 12462
Greece Athens, Greece, 15125
Greece Athens, Greece, 11527
Greece Corfu, Greece, 49100
Greece Heraklion, Greece, 71500
Greece Ioannina, Greece, 45500
Greece Larissa, Greece, 41110
Greece Rio, Greece, 26504
Greece Thessaloniki, Greece, 55535
Greece Thessaloniki, Greece, 56429
Greece Thessaloniki, Greece, 57010